A Synthetic MVA-based SARS-CoV-2 Vaccine, GEO-CM04S1, for the Prevention of COVID-19 Infection

NCT04639466 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

119

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19 Infection

Interventions

DRUG: Placebo Administration
BIOLOGICAL: Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1

Sponsor

GeoVax, Inc.